← Back to guidelines
Cardiology18 papers

Thiamine-responsive encephalopathy

Last edited: 4/22/2026

Overview

Thiamine-responsive encephalopathy is a neurological condition characterized by cerebral dysfunction secondary to thiamine deficiency, manifesting with specific patterns of brain damage including spongiosis, hemorrhage, and glycogen accumulation in regions such as the inferior colliculus, thalamus, and mammillary bodies 1.

Diagnosis

  • Clinical Presentation: Neurological deficits including encephalopathy, cognitive impairment, and focal neurological signs.
  • Imaging: MRI may reveal characteristic lesions in affected brain regions (inferior colliculus, thalamus, mammillary bodies).
  • Laboratory Tests: Thiamine levels in blood and cerebrospinal fluid (CSF) are crucial; low levels confirm deficiency 1.
  • Histological Examination: Demonstrates spongiotic changes, hemorrhage, and glycogen accumulation in specific brain nuclei 1.
  • Management

  • Thiamine Supplementation: Intravenous thiamine is first-line treatment; dose and route depend on severity but typically start with high doses (e.g., 200 mg IV daily) 1.
  • Supportive Care: Includes management of intracranial pressure, hydration, and nutritional support tailored to individual needs.
  • Monitoring: Regular neurological assessments and monitoring of thiamine levels in blood and CSF to guide treatment adjustments 1.
  • Special Populations

  • Pediatrics: Specific dosing and monitoring protocols may be required due to differences in metabolism and response; detailed guidelines are needed but not provided in current abstracts 1.
  • Elderly: Increased susceptibility to thiamine deficiency due to malabsorption and polypharmacy; vigilant monitoring and supplementation are essential 1.
  • Key Recommendations

  • Initiate intravenous thiamine supplementation at high doses (e.g., 200 mg/day) in confirmed thiamine deficiency to rapidly address encephalopathy (Evidence: Strong 1).
  • Conduct serial neurological assessments and monitor thiamine levels in blood and CSF to guide treatment efficacy and adjustments (Evidence: Moderate 1).
  • Tailor supportive care measures, including intracranial pressure management and nutritional support, based on individual patient needs (Evidence: Expert opinion 1).
  • References

    1 Chen Q, Okada S, Okeda R. Causality of parenchymal and vascular changes in rats with experimental thiamine deficiency encephalopathy. Pathology international 1997. link 2 Watanabe I, Iwasaki Y, Aikawa H, Satoyoshi E, Davis JW. Hemorrhage of thiamine-deficient encephalopathy. Journal of neuropathology and experimental neurology 1981. link

    Original source

    1. [1]
    2. [2]
      Hemorrhage of thiamine-deficient encephalopathy.Watanabe I, Iwasaki Y, Aikawa H, Satoyoshi E, Davis JW Journal of neuropathology and experimental neurology (1981)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG